骨质疏松症的药物治疗

被引：18

作者：

张燕燕

卢春燕

刘斌

陈德才

机构：

[1] 四川大学华西医院内分泌科

来源：

中国骨质疏松杂志 | 2007年 / 11期

关键词：

骨质疏松; 骨转换抑制剂; 骨形成促进剂; 解偶联剂;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

1002 ; 100201 ;

摘要：

骨质疏松症是以骨强度受损,骨折危险性增加为主要表现的骨骼疾病。其治疗药物种类繁多,主要包括钙和维生素D,骨转换抑制剂,骨形成促进剂与解偶联剂四大类。钙和维生素D是预防骨质疏松的基础药物。二膦酸盐可以用于各种骨质疏松的治疗。选择性雌激素受体调节剂适用于无明显更年期症状、无血栓栓塞性疾病的绝经后骨质疏松症患者。降钙素主要适用于高转换型骨质疏松症伴疼痛明显者。雌激素适用于骨质疏松症的预防,能有效降低非椎体骨折率。小剂量甲状旁腺激素可以有效促进骨骼重建,预防骨折发生。锶盐能保持骨形成的同时减少骨吸收,有效降低椎体和非椎体骨折率。

引用

页码：809 / 813

页数：5

共 10 条

[1] Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene [J].

McClung, Michael R. ;

Siris, Ethel ;

Cummings, Steve ;

Bolognese, Michael ;

Ettinger, Mark ;

Moffett, Alfred ;

Emkey, Ronald ;

Day, Wesley ;

Somayaji, Veena ;

Lee, Andrew .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2006, 13 (03) :377-386

[2]

Calcitonin: Physiological Actions and Clinical Applications[J] . A.M. Inzerillo ,,M. Zaidi ,,C.L.-H. Huang ,.Journal of Pediatric Endocrinology and Metabolism . 2004 (7)

[3] Efficacy and safety of ibandronate given by intravenous injection once every 3 months [J].

Adami, S ;

Felsenberg, D ;

Christiansen, C ;

Robinson, J ;

Lorenc, RS ;

Mahoney, P ;

Coutant, K ;

Schimmer, RC ;

Delmas, R .

BONE, 2004, 34 (05) :881-889

[4]

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study[J] . H. A. P. Pols,D. Felsenberg,D. A. Hanley,J. ?tepán,M. Mu?oz-Torres,T. J. Wilkin,G. Qin-sheng,A. M. Galich,K. Vandormael,A. J. Yates,B. Stych.Osteoporosis International . 1999 (5)

[5]

Biovailability of fluoride in postmenopausal women: Comparative study between sodium fluoride and disodium monofluorophosphate-calcium carbonate[J] . Frédéric Lioté,Christophe Bardin,Amélie Liou,Agnès Brouard,Jean-Loup Terrier,Daniel Kuntz.Calcified Tissue International . 1992 (3)

[6]

Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis. Ann Cranney,Peter Tugwell,Nicole Zytaruk,et al. Endocrine Reviews . 2002

[7]

The effects of strontiumranelate on the risk of vertebral fracture in women with postm-enopausal osteoporosis. Meunier P J,Roux C,Seeman E,et al. The New England Journal of Medicine . 2004

[8]

Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. The Journal of The American Medical Association . 2001

[9]

Fracture prevention with vitaminD supplementation: a meta-analysis of randomized controlled trials. Bischoff-Ferrari HA,Willett WC,Wong JB, et al. The Journal of The American Medical Association . 2005

[10]

Guideline for clinical application of hormone supplementary treatment. Menopause unit of gynaecology and obstetrics association. Chinese Journal of obstetrics and gynaecology . 2004

← 1 →